Avivagen Announces Pet Product Sale and Management Change

OTTAWA, Ontario–(BUSINESS WIRE)– Brightening inc. (TSXV: VIV, OTCQB: VIVXF) (“Avivagen”), a life sciences company focused on the development and commercialization of products for livestock, companion animals and human applications that safely enhance the dietary intake and support immune function, thereby supporting overall health and performance, is pleased to announce significant new and expanded sales of the company’s pet products. New sales include an order for 1,500 units of Vivamune from an existing distribution partner in Taiwan, as well as two new customers in Mexico.

The order of 1,500 units represents the largest single order from Avivagen’s Taiwan-based distribution partner this year and reflects increased consumer awareness and interest in Vivamune in Taiwan. OxC-beta complex is also used as a key ingredient by a major premium dog food producer in Taiwan, as the company recently expanded its line of dog food products containing OxC-beta to include dog foods in preserves in addition to its dry croquettes.

The first of two new customers in Mexico, an independent distributor of high quality nutritional products for dogs, has ordered 4,000 units of white label products which it will market under its own brand. The second Mexican customer has placed an initial order for 500 units of Vivamune, which follows its own successful internal study and which it plans to market through veterinary clinics and hospitals.

“We now see great interest and great opportunity for Avivagen in the companion animal market. These new sales and customer wins in key markets like Taiwan and Mexico follow sales in Canada and the United States, and are clear signs of growing demand for our pet product as an important of companion animal health promotion,” said Kym Anthony, Managing Director. Officer of Avivagen. “We are excited to expand our customer base and recurring business in these areas.”

Avivagen also announced today the departure of Chris Boland as Chief Financial Officer. The company plans to announce a new manager for its finance functions in the near term.

“We thank Chris for his efforts and dedication to Avivagen and look forward to announcing a new Chief Financial Officer to support the next phase of our growth globally,” adds Anthony.

About Avivagen

Avivagen is a life sciences company focused on the development and commercialization of products for livestock, companion animals and human applications that, by safely supporting immune function, promote overall health and performance. It is a public company listed on the TSX Venture Exchange under the symbol VIV and headquartered in Ottawa, Canada at the partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The content of the website is expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen’s discoveries of β-carotene and other carotenoids, compounds that give certain fruits and vegetables their vibrant colors. By supporting immune function, the technology provides a non-antibiotic way to promote health and growth. OxC-beta™ Livestock is a proprietary product that has proven to be an effective and economical alternative to antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, Vietnam, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to eliminate all antibiotics in food as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product works as well and, sometimes, in some respects, better than antibiotics in feed.

Forward-looking statements

This press release contains certain forward-looking statements based on management’s current expectations. Forward-looking statements involve risks and uncertainties associated with Avivagen Inc.’s business and the environment in which the company operates. All statements contained herein that are not statements of historical fact can be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “target”, “hope”, “probable”, “may”, “plan”, “eventually”, “potentially”, “pursue”, “seem”, “should”, “if”, “will”, “would” and similar expressions.

The statements in this press release regarding the future growth and prospects of Avivagen and the potential for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For example, Avivagen’s products may not be accepted by the market or approved by regulatory authorities in new jurisdictions or for new applications and may not be widely accepted as substitutes for antibiotics as growth promoters in feed due to many factors, many of which are beyond Avivagen’s control. . Readers are referred to the risk factors associated with the activities of Avivagen presented in the most recent management report and analysis of the financial situation of Avivagen available at www.SEDAR.com. Except as required by law, Avivagen undertakes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220729005070/en/

Brightening inc.
Drew Basek
Investor Relations Director
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
Email: d.basek@avivagen.com

Kym Anthony
Chief executive officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head office phone: 613-949-8164
Website: www.avivagen.com

Source: Avivagen Inc.

Comments are closed.